香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 自願公告 戰略合作備忘錄 本公告乃由中國健康科技集團控股有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）自願作出，以告知本公司股東及潛在投資者有關本集團之最新業務發展。 戰略合作備忘錄 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2025年9月26日，本公司與無憂健 康（控股）集團有限公司（「無憂健康」）訂立不具法律效力及約束力的戰略合作備 忘錄（「戰略合作備忘錄」），根據戰略合作備忘錄，雙方同意開展有關社區大健康 服務平臺建設及大健康產品開發與銷售方面的合作（「合作業務」）。 本公司為一家投資控股公司，其附屬公司主要在在中華人民共和國（「中國」）從事 林業管理業務、人參業務及健康產品業務。 無憂健康為一家在香港成立的有限公司，致力於大健康服務平臺建設，旨在於中 國內地為客戶打造便捷的綜合性健康服務平臺。 ...

Core Viewpoint - The stock price of Suning.com (ST Yigou, 002024.SZ) fell by 4.81% to 1.78 CNY per share following the announcement of a major shareholder's plan to reduce their stake [1][2] Group 1: Shareholder Reduction Plan - Hangzhou Haoyue Enterprise Management Co., Ltd. plans to reduce its holdings by up to 263 million shares, representing 2.85% of the total share capital, within three months after the announcement [1][2] - The reduction will occur through centralized bidding and block trading, with a maximum of 1% through centralized bidding and 1.85% through block trading [1] - Hangzhou Haoyue is not a controlling shareholder and the reduction will not affect the company's control or ongoing operations [2] Group 2: Shareholding Structure - As of the announcement date, Hangzhou Haoyue held 1.861 billion shares, accounting for 20.09% of Suning.com, making it the largest shareholder [1][4] - Zhang Jindong and his concerted actions hold a combined 21.85%, making them the second-largest shareholders, with Zhang directly holding 17.7% [4] Group 3: Financial Performance - For the first half of 2025, Suning.com reported revenue of 25.895 billion CNY, a year-on-year increase of 0.44%, and a net profit of 48.693 million CNY, up 230.03% [4][5] - The company has benefited from the old-for-new subsidy policy and has been expanding its national store layout and local retail service capabilities [4]

Summary of Key Points Core Viewpoint - The strategic cooperation agreement signed between Anhui Fuhuang Steel Structure Co., Ltd. and China 22nd Metallurgical Group Co., Ltd. aims to enhance collaboration in engineering contracting and technology application, promoting mutual benefits and resource optimization [3][7]. Agreement Overview - The strategic cooperation agreement is a framework and intention-based arrangement, not involving specific amounts, and does not require board or shareholder approval [2][3]. - The agreement does not constitute a related party transaction, and it is not classified as a major asset restructuring under relevant regulations [3][4]. Parties Involved - China 22nd Metallurgical Group Co., Ltd. was established on April 1, 1997, with a registered capital of approximately 339.33 million yuan [4]. Main Content of the Cooperation Agreement - The cooperation principles include equality, mutual benefit, resource sharing, and long-term stability [5][6]. - The cooperation will focus on domestic and international engineering contracting and technology applications, with both parties leveraging their respective strengths [6][7]. Impact on the Company - The agreement aligns with the company's strategic development needs and is expected to enhance its core competitiveness [7]. - The agreement is not anticipated to have a significant impact on the company's 2025 operating performance, with future impacts dependent on the implementation of subsequent projects [7].

人民财讯9月23日电，青龙管业（002457）9月23日公告，公司与中国中材国际（600970）工程股份有限 公司(简称"中材国际")近日签订战略合作框架协议，双方以市场化方式积极推进合作，拓展双方在国际 化经营、境外产能布局等方面的合作空间，实现互利共赢，协议有效期限为3年。 ...

人民财讯9月23日电，据东安动力（600178）官微，9月22日，环新集团常务副总经理开柏林一行访问东 安动力，双方共同签署战略合作框架协议。此次协议的签署，为双方战略合作注入了新动力。双方将加 速推动各项合作落地，旨在产业变革中实现强强联合、优势互补，共同开创互利共赢的高质量发展新局 面。 ...

Core Viewpoint - The announcement of an exclusive cooperation agreement between Zhixiang Jintai and Kangzhe Pharmaceutical is expected to significantly enhance the company's market position and financial performance through the commercialization of two monoclonal antibodies [1][2]. Group 1: Agreement Details - Zhixiang Jintai signed an exclusive cooperation agreement with Kangzhe Pharmaceutical and its subsidiaries, which includes a total payment of up to 260 million RMB, consisting of upfront and milestone payments [1]. - The agreement grants Zhixiang Jintai exclusive commercialization rights for Weikang Duta monoclonal injection and Sileweimi monoclonal injection in mainland China and the Asia-Pacific region [1]. Group 2: Market Impact - Following the announcement, Zhixiang Jintai's stock price rose by 1.41% to 33.79 RMB per share, with a trading volume of 129 million RMB, reflecting positive market sentiment [2]. - Despite a slight decline of 0.18% in the stock price over the past seven trading days, the announcement has boosted investor confidence and increased attention on the company [2]. Group 3: Strategic Outlook - The cooperation is seen as a strategic move to enhance Zhixiang Jintai's market competitiveness and position within the biopharmaceutical industry, responding proactively to future market demands [1][4]. - The company aims to deepen resource integration with key partners, enhance R&D capabilities, and optimize product structure to drive overall transformation and long-term growth [4].

Group 1 - Shengxin Lithium Energy plans to acquire 21% stake in Qicheng Mining for 1.456 billion yuan, increasing its ownership to 70% [4] - Tianpu Co. has seen its stock rise 279.73% over 14 consecutive trading days, but the acquirer Zhonghao Xinying has no asset injection plan [5] - Hangdian Co. reports losses in its optical communication business while its copper foil business is still in the early stages [6][7] Group 2 - Tianchuang Fashion is launching a shareholder reward activity, offering 70% discount coupons to shareholders [8] - Beiliang Co. is collaborating with Tonghuashun to host a "Shareholder Festival" for past investors [9] - Xinxiang Chemical Fiber will undergo a 90-day orderly shutdown for equipment upgrades, affecting 31,200 tons/year capacity and expected revenue loss of approximately 185 million yuan [10] Group 3 - Bozhong Precision plans to transfer 18.29% stake in Suzhou Linghou Robotics for 64 million yuan [11] - Tiancai Self-Control has received a project confirmation from a leading domestic new energy vehicle company for seat assembly, expected to start production in June 2026 [12] - Huazi Industrial's subsidiary plans to sell dairy farm assets for 38.5 million yuan, impacting current profits by approximately 11.7 million yuan [13] Group 4 - Oriental Pearl plans to invest in a special fund to acquire equity in Chaoyuan Digital Technology, committing 244 million yuan [14] - Daotong Technology intends to transfer 46% stake in Shenzhen Saifang Technology for 109 million yuan, focusing on core business development [15] - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information to enhance online sales channels for its aesthetic medicine segment [16] Group 5 - Dingxin Communications clarifies that its technology authorization from Pingtouge is unrelated to AI chip development [17] - Changchuan Technology expects a net profit increase of 131.39% to 145.38% year-on-year for the first three quarters of 2025, driven by strong semiconductor demand [18] Group 6 - Guangdong Construction has won a construction contract worth 1.924 billion yuan for a property reconstruction project [19] - Youxunda is expected to win a procurement project from the State Grid worth approximately 107 million yuan, representing 10.55% of its 2024 revenue [20] - Samsung Medical anticipates winning procurement projects from the State Grid totaling about 193 million yuan [21] Group 7 - Baiyun Electric is a candidate for multiple procurement projects from the State Grid, with a total expected amount of 162 million yuan [22] - *ST Weihe is a candidate for a 141 million yuan engineering project [23] - Plad has signed a strategic cooperation agreement with a well-known international power tool brand for over 700 million yuan in purchases over five years [25] Group 8 - Lanhua Kecai has signed a strategic cooperation agreement with Panhu Power for joint development of axial flux motors [26] - Zhixiang Jintai has entered into commercialization agreements for two monoclonal antibody injections, gaining exclusive rights in various regions [27] - Honggong Technology plans to invest up to 450 million yuan in a project with the Changsha Economic Development Zone [28] Group 9 - Zhejiang Medicine's major shareholder plans to reduce its stake by up to 1% [29] - Su Yan Jingshen's directors plan to collectively increase their holdings by 1.9 to 2.66 million yuan [30] - Zhongdian Electric's shareholder intends to reduce its stake by up to 3% [32] Group 10 - Sanfu New Science plans to repurchase shares worth 10 to 15 million yuan for employee stock incentives [41] - Guiyan Platinum plans to raise up to 1.291 billion yuan for technology innovation and industry upgrades [42] - Zhongjing Electronics plans to raise up to 700 million yuan, with the controlling shareholder participating in the subscription [43]

Core Viewpoint - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information Technology (Shanghai) Co., Ltd., aiming for a long-term partnership based on mutual benefits and resource sharing [1] Group 1: Strategic Partnership - The agreement establishes a comprehensive strategic partnership between Lepu Medical and Hanhai Information [1] - Hanhai Information is a core entity of Meituan in Shanghai, possessing complete operational rights for Meituan and Dianping [1] Group 2: Market Promotion and Operations - Hanhai Information will be authorized by Lepu Medical to promote and operate the medical beauty segment's brands [1]

Core Viewpoint - The announcement highlights a strategic partnership between Yingboer and Fengli Intelligent aimed at leveraging their respective strengths in various sectors, including new energy vehicles and intelligent manufacturing, to achieve mutual benefits and expand business opportunities [1] Group 1: Strategic Cooperation - Yingboer signed a strategic cooperation agreement with Fengli Intelligent on April 21, 2025, focusing on deep collaboration in fields such as new energy vehicles, joint modules, engineering machinery, eVTOL, and intelligent manufacturing [1] - The partnership aims to integrate Yingboer's competitive advantages in motor and electronic control with Fengli Intelligent's expertise in harmonic and planetary reducers, creating integrated product capabilities [1] Group 2: Business Expansion - The collaboration is expected to enhance Yingboer's layout in the joint module sector and further expand the application areas of its motor and electronic control products, opening new avenues for business growth [1] - The company maintains an open and innovative approach, actively monitoring developments and technological demands across various fields to identify new business areas and product types based on market needs and technological trends [1]

Group 1 - The core point of the article is that Pulaide has signed a strategic cooperation agreement with a well-known international electric tool brand (referred to as "Company Y"), which is expected to result in a total procurement volume exceeding RMB 700 million over the next five years, accounting for over 80% of the company's audited revenue for 2024 [1][2] - The agreement does not require approval from the company's board of directors or shareholders and does not involve related party transactions or constitute a major asset restructuring as defined by regulations [1] - Company Y is a leading brand in the electric tool sector and a frontrunner in the European lithium battery tool industry, maintaining a long-term stable business relationship with Pulaide and ranking among its top ten customers [2] Group 2 - The strategic cooperation is expected to strengthen the long-term partnership between Pulaide and Company Y, facilitating deep collaboration in technology innovation, market expansion, and commercialization [2] - The partnership is anticipated to bring stable, large-scale orders, enhance revenue growth and global market share, and improve brand reputation for Pulaide [2] - In the first half of the year, Pulaide achieved revenue of RMB 461 million, a year-on-year increase of 11.98%, and a net profit attributable to shareholders of RMB 45.65 million, up 14.23% year-on-year [3]